Key result
DPP-4 inhibitors demonstrated acceptable cardiovascular safety profiles across major trials (SAVOR-TIMI 53, EXAMINE, TECOS) for CV death, nonfatal MI, and stroke in T2DM patients.
Answers are grounded in this paper and cite their sources.
The incretin-based therapies, dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon-like peptide-1 (GLP-1) analogs, are important new classes of therapy for type 2 diabetes mellitus (T2DM). These agents prolong the action of the incretin hormones, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), by inhibiting their breakdown. The incretin hormones improve glycemic control in T2DM by increasing insulin secretion and suppressing glucagon levels. The cardiovascular (CV) effects of the incretin-based therapies have been of substantial interest since 2008, when the US Food and Drug Administration began to require that all new therapies for diabetes undergo rigorous assessment of CV safety through large-scale CV outcome trials. This article reviews the most recent CV outcome trials of the DPP-4 inhibitors (SAVOR-TIMI 53, EXAMINE, and TECOS) as evidence that the incretin-based therapies have acceptable CV safety profiles for patients with T2DM. The studies differ with regard to patient population, trial duration, and heart failure outcomes but show similar findings for CV death, nonfatal myocardial infarction, and stroke, as well as hospitalization for unstable angina.
No takes yet. Share an insight, caveat, or question.
White et al. (2016) conducted a review in Type 2 diabetes mellitus. Incretin-based therapies (DPP-4 inhibitors and GLP-1 analogs) was evaluated on Cardiovascular death, nonfatal myocardial infarction, stroke, and hospitalization for unstable angina. DPP-4 inhibitors demonstrated acceptable cardiovascular safety profiles across major trials (SAVOR-TIMI 53, EXAMINE, TECOS) for CV death, nonfatal MI, and stroke in T2DM patients.
Synapse has enriched 10 related papers. Consider them for comparative context: